Research Roundup


Debbie Rigby rounds up the latest in research news

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections

A large population-based cohort study using US-based databases has shown that the risk for severe and nonsevere UTI events among those initiating SGLT-2 inhibitor therapy was similar to that among patients initiating treatment with other second-line antidiabetic medications. The incident rate for severe UTIs in patients taking SGLT-2 inhibitors was 1.76 per 1000 person-years, compared to 1.77 in the DPP-4 inhibitor group; similar rates were observed compared to GLP-1 agonists (IR 2.15 vs 2.96) In addition, SGLT-2 inhibitors were not associated with increased risk for outpatient UTIs.

Ann Intern Med. 2019;171(4):248-256.

 

Metoprolol for the Prevention of Acute Exacerbations of COPD

In this prospective, randomized trial of 532 patients with COPD the time until the first COPD exacerbation was similar in the extended-release metoprolol group and the placebo group. Hospitalization for exacerbation was more common among the patients treated with metoprolol.

N Engl J Med 2019; 381:2304-2314.

 

Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors

Three large cardiovascular outcomes trials have demonstrated consistent reductions in heart failure events among patients with type 2 diabetes mellitus with, or at risk for, atherosclerotic cardiovascular disease. Another trial recently showed that an SGLT2 inhibitor, canagliflozin, also significantly reduced heart failure events among patients with type 2 diabetes mellitus and albuminuric chronic kidney disease.

Am J Cardiol 2019;124:S20−S27

Supplementary video

 

How can green tea polyphenols affect drug metabolism and should we be concerned?

Green tea with its polyphenols can lead to potentially lead to serious drug interactions. Clinically significant drug interactions may occur with tacrolimus and warfarin. No clinically relevant drug interactions were reported for digoxin, sildenafil, simvastatin, and rosuvastatin.

Expert Opinion on Drug Metabolism & Toxicology, 2019;15(12):989-991.

Previous Pharmacist directly imported hormone and ED treatments
Next Fire-affected pharmacies step in to help

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.